Corporate Profile
AxoGen, Inc. is an emerging regenerative medicine company focused on the commercialization of proprietary products and technologies for peripheral nerve reconstruction and regeneration.
Headquarters: Alachua, FL
Number of Employees: 46
Products and Services: Peripheral Nerve Reconstruction
Peripheral nerves provide the pathways for both motor and sensory signals throughout the body and their damage can result in the loss of function and feeling. In order to improve surgical reconstruction and regeneration of peripheral nerves, AxoGen has developed and licensed patented and patent-pending technologies, which are used in its portfolio of products.
This portfolio includes Avance® Nerve Graft, the only commercially available processed nerve allograft for bridging severed peripheral nerves. AxoGen's portfolio also includes AxoGuard® Nerve Connector, a coaptation aid allowing for close approximation of severed nerves, and AxoGuard® Nerve Protector, a bioscaffold used to reinforce a coaptation site, wrap a partially severed nerve or isolate and protect nerve tissue. AxoGen is bringing the science of nerve repair to life with thousands of surgical implants of AxoGen products performed in hospitals and surgery centers across the United States, including military hospitals serving U.S. service men and women.
Strong Performance
dollars in millions, except where noted
Financial Summary
dollars in thousands
| 1Q 2012 | 4Q 2011 | 1Q 2011 | 2011 | |
| Income Statement: | ||||
| Net Revenues | $1,653 | $1,362 | $1,121 | $4,849 |
| Gross Profit* | $1,214 | $914 | $783 | $2,422 |
| Gross Margin | 73% | 67% | 70% | 50% |
| Net Income (Loss) | ($2,109) | ($2,153) | ($2,667) | ($9,220) |
| Balance Sheet: | ||||
| Cash & Cash Equivalents | $5,642 | $8,191 | $5,642 | $8,191 |
| *Note: Excludes one-time write-off inventory | ||||
Business summary
AxoGen is a regenerative medicine company with a proprietary product portfolio for peripheral nerve reconstruction and regeneration in a wide range of nerve gap sizes.
The January, 2012 edition of Microsurgery contains an article summarizing the RANGER study results to date, reporting over 87% meaningful recovery in sensory, motor and mixed nerve injuries treated with the Avance® Nerve Graft (Published Microsurgery DOI: 10.1002/micr.20975.)
"It is commonly accepted among surgeons who do peripheral nerve repair that success of surgery depends on the type of injury, length of nerve discontinuity, the patient’s age and the type of nerve. Our study findings show that with processed nerve allograft, patients can have meaningful recovery regardless of these factors."
"Based on our findings, the information I use to counsel my patients prior to surgery will change — this is a paradigm shift."
Darrell Brooks, M.D., plastic surgeon,
The Buncke Clinic
| Company Leadership | Company Contact |
| Karen Zaderej - Chief Executive Officer | Greg Freitag |
| Greg Freitag - Chief Financial Officer | Chief Financial Officer |
| Jill Schiaparelli - SVP Business Strategy & Marketing | AxoGen, Inc |
| John Engels - Vice President | 13859 Progress Blvd., Suite 100 |
| Mark Friedman, Ph.D. - VP Regulatory Affairs | Alachua, FL 32615 |
| Brad Hedger - VP of Sales | P 972.308.6830 |
| axogeninc.com |
Investor Contact
1230 Peachtree Street
19th Floor
Atlanta, GA 30309
P 404.942.3369
cockrellgroup.com
